Selected research
Market Analysis & Forecast
Global Diabetes Screening Market Analysis and Forecast 2026-2032
Market perspective
The global Diabetes Screening market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Diabetes Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Diabetes Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Diabetes Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Diabetes Screening is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Diabetes Screening include InSphero AG, Abbott Laboratories, American Laboratory Products Company (ALPCO), Beckmann Coulter Inc., Bio-Rad Laboratories Inc., Ortho Clinical Diagnostics Inc., F. Hoffmann-la Roche Ltd, Siemens AG and PTS Diagnostics, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Diabetes Screening, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Diabetes Screening, also provides the revenue of main regions and countries. Of the upcoming market potential for Diabetes Screening, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Diabetes Screening revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Diabetes Screening market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Diabetes Screening revenue, projected growth trends, production technology, application and end-user industry.
Diabetes Screening Segment by Company
InSphero AG
Abbott Laboratories
American Laboratory Products Company (ALPCO)
Beckmann Coulter Inc.
Bio-Rad Laboratories Inc.
Ortho Clinical Diagnostics Inc.
F. Hoffmann-la Roche Ltd
Siemens AG
PTS Diagnostics
Diabetes Screening Segment by Type
Instrument
Test Suite
Reagents
Diabetes Screening Segment by Application
Hospital
Specialty Clinic
Diagnostic Center
Home Care
Academic Research Institution
Diabetes Screening Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Diabetes Screening market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Diabetes Screening and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Diabetes Screening.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Diabetes Screening in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Diabetes Screening company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Diabetes Screening revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Instrument
- Test Suite
- Reagents
Applications
- Hospital
- Specialty Clinic
- Diagnostic Center
- Home Care
- Academic Research Institution
Companies covered
- InSphero AG
- Abbott Laboratories
- American Laboratory Products Company (ALPCO)
- Beckmann Coulter Inc.
- Bio-Rad Laboratories Inc.
- Ortho Clinical Diagnostics Inc.
- F. Hoffmann-la Roche Ltd
- Siemens AG
- PTS Diagnostics
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Diabetes Screening Market by Type
- 1.2.1 Global Diabetes Screening Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 Instrument
- 1.2.3 Test Suite
- 1.2.4 Reagents
- 1.3 Diabetes Screening Market by Application
- 1.3.1 Global Diabetes Screening Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 Hospital
- 1.3.3 Specialty Clinic
- 1.3.4 Diagnostic Center
- 1.3.5 Home Care
- 1.3.6 Academic Research Institution
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Diabetes Screening Market Dynamics
- 2.1 Diabetes Screening Industry Trends
- 2.2 Diabetes Screening Industry Drivers
- 2.3 Diabetes Screening Industry Opportunities and Challenges
- 2.4 Diabetes Screening Industry Restraints
3 Global Growth Perspective
- 3.1 Global Diabetes Screening Market Perspective (2021-2032)
- 3.2 Global Diabetes Screening Growth Trends by Region
- 3.2.1 Global Diabetes Screening Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Diabetes Screening Market Size by Region (2021-2026)
- 3.2.3 Global Diabetes Screening Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Diabetes Screening Revenue by Players
- 4.1.1 Global Diabetes Screening Revenue by Players (2021-2026)
- 4.1.2 Global Diabetes Screening Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Diabetes Screening Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Diabetes Screening Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Diabetes Screening Key Players Headquarters & Area Served
- 4.4 Global Diabetes Screening Players, Product Type & Application
- 4.5 Global Diabetes Screening Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Diabetes Screening Market CR5 and HHI
- 4.6.3 2025 Diabetes Screening Tier 1, Tier 2, and Tier 3
5 Diabetes Screening Market Size by Type
- 5.1 Global Diabetes Screening Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Diabetes Screening Revenue by Type (2021-2032)
- 5.3 Global Diabetes Screening Revenue Market Share by Type (2021-2032)
6 Diabetes Screening Market Size by Application
- 6.1 Global Diabetes Screening Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Diabetes Screening Revenue by Application (2021-2032)
- 6.3 Global Diabetes Screening Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 InSphero AG
- 7.1.1 InSphero AG Company Information
- 7.1.2 InSphero AG Business Overview
- 7.1.3 InSphero AG Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.1.4 InSphero AG Diabetes Screening Product Portfolio
- 7.1.5 InSphero AG Recent Developments
- 7.2 Abbott Laboratories
- 7.2.1 Abbott Laboratories Company Information
- 7.2.2 Abbott Laboratories Business Overview
- 7.2.3 Abbott Laboratories Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.2.4 Abbott Laboratories Diabetes Screening Product Portfolio
- 7.2.5 Abbott Laboratories Recent Developments
- 7.3 American Laboratory Products Company (ALPCO)
- 7.3.1 American Laboratory Products Company (ALPCO) Company Information
- 7.3.2 American Laboratory Products Company (ALPCO) Business Overview
- 7.3.3 American Laboratory Products Company (ALPCO) Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.3.4 American Laboratory Products Company (ALPCO) Diabetes Screening Product Portfolio
- 7.3.5 American Laboratory Products Company (ALPCO) Recent Developments
- 7.4 Beckmann Coulter Inc.
- 7.4.1 Beckmann Coulter Inc. Company Information
- 7.4.2 Beckmann Coulter Inc. Business Overview
- 7.4.3 Beckmann Coulter Inc. Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.4.4 Beckmann Coulter Inc. Diabetes Screening Product Portfolio
- 7.4.5 Beckmann Coulter Inc. Recent Developments
- 7.5 Bio-Rad Laboratories Inc.
- 7.5.1 Bio-Rad Laboratories Inc. Company Information
- 7.5.2 Bio-Rad Laboratories Inc. Business Overview
- 7.5.3 Bio-Rad Laboratories Inc. Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.5.4 Bio-Rad Laboratories Inc. Diabetes Screening Product Portfolio
- 7.5.5 Bio-Rad Laboratories Inc. Recent Developments
- 7.6 Ortho Clinical Diagnostics Inc.
- 7.6.1 Ortho Clinical Diagnostics Inc. Company Information
- 7.6.2 Ortho Clinical Diagnostics Inc. Business Overview
- 7.6.3 Ortho Clinical Diagnostics Inc. Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.6.4 Ortho Clinical Diagnostics Inc. Diabetes Screening Product Portfolio
- 7.6.5 Ortho Clinical Diagnostics Inc. Recent Developments
- 7.7 F. Hoffmann-la Roche Ltd
- 7.7.1 F. Hoffmann-la Roche Ltd Company Information
- 7.7.2 F. Hoffmann-la Roche Ltd Business Overview
- 7.7.3 F. Hoffmann-la Roche Ltd Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.7.4 F. Hoffmann-la Roche Ltd Diabetes Screening Product Portfolio
- 7.7.5 F. Hoffmann-la Roche Ltd Recent Developments
- 7.8 Siemens AG
- 7.8.1 Siemens AG Company Information
- 7.8.2 Siemens AG Business Overview
- 7.8.3 Siemens AG Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.8.4 Siemens AG Diabetes Screening Product Portfolio
- 7.8.5 Siemens AG Recent Developments
- 7.9 PTS Diagnostics
- 7.9.1 PTS Diagnostics Company Information
- 7.9.2 PTS Diagnostics Business Overview
- 7.9.3 PTS Diagnostics Diabetes Screening Revenue and Gross Margin (2021-2026)
- 7.9.4 PTS Diagnostics Diabetes Screening Product Portfolio
- 7.9.5 PTS Diagnostics Recent Developments
8 North America
- 8.1 North America Diabetes Screening Revenue (2021-2032)
- 8.2 North America Diabetes Screening Revenue by Type (2021-2032)
- 8.2.1 North America Diabetes Screening Revenue by Type (2021-2026)
- 8.2.2 North America Diabetes Screening Revenue by Type (2027-2032)
- 8.3 North America Diabetes Screening Revenue Share by Type (2021-2032)
- 8.4 North America Diabetes Screening Revenue by Application (2021-2032)
- 8.4.1 North America Diabetes Screening Revenue by Application (2021-2026)
- 8.4.2 North America Diabetes Screening Revenue by Application (2027-2032)
- 8.5 North America Diabetes Screening Revenue Share by Application (2021-2032)
- 8.6 North America Diabetes Screening Revenue by Country
- 8.6.1 North America Diabetes Screening Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Diabetes Screening Revenue by Country (2021-2026)
- 8.6.3 North America Diabetes Screening Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Diabetes Screening Revenue (2021-2032)
- 9.2 Europe Diabetes Screening Revenue by Type (2021-2032)
- 9.2.1 Europe Diabetes Screening Revenue by Type (2021-2026)
- 9.2.2 Europe Diabetes Screening Revenue by Type (2027-2032)
- 9.3 Europe Diabetes Screening Revenue Share by Type (2021-2032)
- 9.4 Europe Diabetes Screening Revenue by Application (2021-2032)
- 9.4.1 Europe Diabetes Screening Revenue by Application (2021-2026)
- 9.4.2 Europe Diabetes Screening Revenue by Application (2027-2032)
- 9.5 Europe Diabetes Screening Revenue Share by Application (2021-2032)
- 9.6 Europe Diabetes Screening Revenue by Country
- 9.6.1 Europe Diabetes Screening Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Diabetes Screening Revenue by Country (2021-2026)
- 9.6.3 Europe Diabetes Screening Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Diabetes Screening Revenue (2021-2032)
- 10.2 China Diabetes Screening Revenue by Type (2021-2032)
- 10.2.1 China Diabetes Screening Revenue by Type (2021-2026)
- 10.2.2 China Diabetes Screening Revenue by Type (2027-2032)
- 10.3 China Diabetes Screening Revenue Share by Type (2021-2032)
- 10.4 China Diabetes Screening Revenue by Application (2021-2032)
- 10.4.1 China Diabetes Screening Revenue by Application (2021-2026)
- 10.4.2 China Diabetes Screening Revenue by Application (2027-2032)
- 10.5 China Diabetes Screening Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Diabetes Screening Revenue (2021-2032)
- 11.2 Asia Diabetes Screening Revenue by Type (2021-2032)
- 11.2.1 Asia Diabetes Screening Revenue by Type (2021-2026)
- 11.2.2 Asia Diabetes Screening Revenue by Type (2027-2032)
- 11.3 Asia Diabetes Screening Revenue Share by Type (2021-2032)
- 11.4 Asia Diabetes Screening Revenue by Application (2021-2032)
- 11.4.1 Asia Diabetes Screening Revenue by Application (2021-2026)
- 11.4.2 Asia Diabetes Screening Revenue by Application (2027-2032)
- 11.5 Asia Diabetes Screening Revenue Share by Application (2021-2032)
- 11.6 Asia Diabetes Screening Revenue by Country
- 11.6.1 Asia Diabetes Screening Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Diabetes Screening Revenue by Country (2021-2026)
- 11.6.3 Asia Diabetes Screening Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Diabetes Screening Revenue (2021-2032)
- 12.2 SAMEA Diabetes Screening Revenue by Type (2021-2032)
- 12.2.1 SAMEA Diabetes Screening Revenue by Type (2021-2026)
- 12.2.2 SAMEA Diabetes Screening Revenue by Type (2027-2032)
- 12.3 SAMEA Diabetes Screening Revenue Share by Type (2021-2032)
- 12.4 SAMEA Diabetes Screening Revenue by Application (2021-2032)
- 12.4.1 SAMEA Diabetes Screening Revenue by Application (2021-2026)
- 12.4.2 SAMEA Diabetes Screening Revenue by Application (2027-2032)
- 12.5 SAMEA Diabetes Screening Revenue Share by Application (2021-2032)
- 12.6 SAMEA Diabetes Screening Revenue by Country
- 12.6.1 SAMEA Diabetes Screening Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Diabetes Screening Revenue by Country (2021-2026)
- 12.6.3 SAMEA Diabetes Screening Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst